journal article·2020-01-01Open access

miR-324-5p inhibits gallbladder carcinoma cell metastatic behaviours by downregulation of transforming growth factor beta 2 expression

Xinrong Zhang, Lei Zhang, Ming Chen, Dongying Liu

Abstract

Increasing studies have demonstrated that microRNAs (miRNAs) are associated with the metastasis of gallbladder carcinoma (GBC). Recently, miR-324-5p has been reported to be a tumour-suppressive miRNA in many types of malignant cancer. However, the biological function and molecular mechanism of miR-324-5p in GBC still remain largely unknown. Here, we found that miR-324-5p expression was notably down-regulated in both GBC tissues and cells compared with that in normal controls. Downregulated miR-324-5p expression was negatively associated with the status of local invasion and lymph node metastasis and predicted a poor prognosis in GBC patients. Further functional assays revealed that restoration of miR-324-5p significantly suppressed GBC cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and impeded the metastasis of GBC cells in vivo. Moreover, RNA immunoprecipitation (RIP) and dual-luciferase reporter assay confirmed that the transforming growth factor beta 2 (TGFB2) was a direct target gene of miR-324-5p in GBC cells. Mechanically, small interfering RNA (siRNA)-mediated knockdown of TGFB2 partially phenocopied the inhibitory effects of miR-324-5p overexpression on GBC cell metastatic phenotypes. In summary, our findings demonstrated that miR-324-5p targets TGFB2 expression to inhibit GBC cell metastatic behaviors, and implying miR-324-5p as a potential biomarker for diagnostic and therapeutic strategies in GBC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Cancer-related molecular mechanisms research · Cholangiocarcinoma and Gallbladder Cancer Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Digestive Medicine, Tianjin Nankai Hospital

Department of Traditional Chinese Medicine, Geriatric Hospital, Civil Affairs Bureau of Tianjin

Department of Liver Tumor Internal Medicine, Tianjin Nankai Hospital

Department of Integrated Traditional Chinese and Western Medicine, Tianjin Medical University Cancer Institute and Hospital

References (36)

Show source-provided references
1. 10.2147/CLEP.S3735710.2147/CLEP.S37357 ↗
2. 10.1038/nrc142910.1038/nrc1429 ↗
3. Rakic M, Patrlj L, Kopljar M, et al. Gallbladder cancer. Hepatobiliary Surg Nutr. 2014;3:221–226.
4. 10.3748/wjg.v21.i43.1221110.3748/wjg.v21.i43.12211 ↗
5. 10.3322/caac.2133210.3322/caac.21332 ↗
6. 10.1634/theoncologist.2009-030210.1634/theoncologist.2009-0302 ↗
7. 10.1016/S0092-8674(04)00045-510.1016/S0092-8674(04)00045-5 ↗
8. 10.1016/j.molmed.2014.06.00510.1016/j.molmed.2014.06.005 ↗
9. 10.1002/2211-5463.1262310.1002/2211-5463.12623 ↗
10. Zhang Y, Lin P, Zou JY, et al. MiR-216a-5p act as a tumor suppressor, regulating the cell proliferation and metastasis by targeting PAK2 in breast cancer. Eur Rev Med Pharmacol Sci. 2019;23(6):2469–2475.
11. 10.1016/j.biopha.2018.12.12110.1016/j.biopha.2018.12.121 ↗
12. 10.1002/jcb.2861910.1002/jcb.28619 ↗
13. Xu HS, Zong HL, Shang M, et al. MiR-324-5p inhibits proliferation of glioma by target regulation of GLI1. Eur Rev Med Pharmacol Sci. 2014;18(6):828–832.
14. 10.1371/journal.pone.013307410.1371/journal.pone.0133074 ↗
15. 10.3727/096504018X1516618359857210.3727/096504018X15166183598572 ↗
16. 10.1186/s13046-018-0846-810.1186/s13046-018-0846-8 ↗
17. 10.1016/j.devcel.2019.04.01010.1016/j.devcel.2019.04.010 ↗
18. 10.3390/ijms2008204210.3390/ijms20082042 ↗
19. 10.1006/meth.2001.126210.1006/meth.2001.1262 ↗
20. 10.7554/eLife.0500510.7554/eLife.05005 ↗
21. 10.1093/nar/gky114110.1093/nar/gky1141 ↗
22. 10.1186/gb-2003-5-1-r110.1186/gb-2003-5-1-r1 ↗
23. 10.1186/s13046-017-0628-810.1186/s13046-017-0628-8 ↗
24. 10.3322/caac.2126210.3322/caac.21262 ↗
25. 10.21873/anticanres.1108910.21873/anticanres.11089 ↗
26. 10.1016/j.celrep.2014.05.00710.1016/j.celrep.2014.05.007 ↗
27. 10.1002/ijc.3104110.1002/ijc.31041 ↗
28. 10.1016/j.cell.2009.01.00210.1016/j.cell.2009.01.002 ↗
29. 10.1111/jphp.1299510.1111/jphp.12995 ↗
30. 10.1186/s13046-018-0697-310.1186/s13046-018-0697-3 ↗
31. 10.18632/oncotarget.338210.18632/oncotarget.3382 ↗
32. 10.18632/oncotarget.346710.18632/oncotarget.3467 ↗
33. 10.1371/journal.pone.005424910.1371/journal.pone.0054249 ↗
34. 10.1371/journal.pone.018561910.1371/journal.pone.0185619 ↗
35. Peng T, Zhang S, Li W, et al. MicroRNA-141 inhibits glioma cells growth and metastasis by targeting TGF-β2. Am J Transl Res. 2016;8(8):3513–3521.
36. Guo G, Zhang Y, Hu L, et al. MicroRNA-153 affects nasopharyngeal cancer cell viability by targeting TGF-β2. Oncol Lett. 2019;17(1):646–651.